Myriad Genetics Inc (NAS:MYGN)
$ 26.835 0.445 (1.69%) Market Cap: 2.44 Bil Enterprise Value: 2.44 Bil PE Ratio: 0 PB Ratio: 3.29 GF Score: 78/100

Myriad Genetics Inc at Morgan Stanley Healthcare Conference Transcript

Sep 10, 2019 / 12:35PM GMT
Release Date Price: $25.38 (+3.85%)
Anthony Yu;Morgan Stanley;Vice President

Right. I'll go ahead and read the disclosure. Please note that all important disclosures, including personal holding disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk. My name is Anthony Yu. I am Vice President in Morgan Stanley's Healthcare Investment Banking team. I'm joined up here on stage with Mark Capone, CEO of Myriad Genetics. I will just give him a few minutes to give a brief introduction about himself and the company. I'm sure everybody is aware of it.

Mark Christopher Capone
Myriad Genetics, Inc. - CEO, President & Director

All right. Thank you, Anthony, and good morning, and thanks to Morgan Stanley for hosting another outstanding conference. For those who don't know, Myriad was founded about 27 years ago as the pioneer in precision medicine. Precision medicine has dual aims, that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot